List of Excipients in Branded Drug TOLBUTAMIDE

Generic Drugs Containing TOLBUTAMIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	tolbutamide	0378-0215	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	tolbutamide	0378-0215	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	tolbutamide	0378-0215	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	tolbutamide	0378-0215	SODIUM LAURYL SULFATE
Mylan Pharmaceuticals Inc	tolbutamide	0378-0215	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in TOLBUTAMIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	MAGNESIUM STEARATE
1	SILICON DIOXIDE
1	SODIUM LAURYL SULFATE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

Tolbutamide Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Tolbutamide is an established first-generation sulfonylurea with no meaningful modern exclusivity moat. Its commercial opportunity is therefore based on low-cost manufacturing, reliable dissolution, differentiated packaging, and tightly controlled niche distribution rather than novel-molecule pricing. The principal formulation challenge is managing tolbutamide’s low aqueous solubility while preserving tablet robustness, content uniformity, and chemical stability.

What is tolbutamide and where does it fit commercially?

Tolbutamide is an oral sulfonylurea used historically for glycemic control in patients with type 2 diabetes. It stimulates pancreatic beta-cell insulin release and requires residual pancreatic function to produce an effect. The drug has a shorter duration of action than several later sulfonylureas and was marketed historically under the Orinase brand.

Attribute	Tolbutamide
Active ingredient	Tolbutamide
Drug class	First-generation sulfonylurea
Primary dosage form	Immediate-release oral tablet
Historical strengths	Commonly 500 mg; lower strengths also existed in certain markets
Administration	Oral
Therapeutic area	Type 2 diabetes
Regulatory position	Legacy small-molecule product
Exclusivity profile	Foundational patents and historical market protections have expired
Current commercial model	Generic, institutional, specialty, or market-specific supply
Main formulation issue	Low water solubility and dissolution variability

Tolbutamide is commercially disadvantaged by competition from newer sulfonylureas, metformin, DPP-4 inhibitors, GLP-1 therapies, SGLT2 inhibitors, and insulin products. Its low acquisition cost and established chemistry can still support limited commercial programs where price, supply continuity, or formulary access outweighs clinical preference.

FDA labeling for tolbutamide identifies hypoglycemia as a central safety risk and describes use as an adjunct to diet and exercise when non-insulin-dependent diabetes cannot be controlled adequately by diet alone (U.S. Food and Drug Administration [FDA], n.d.-a).

What excipients are used in tolbutamide tablets?

Historical tolbutamide tablets used conventional immediate-release excipient systems. Product-specific inactive ingredients vary by manufacturer and jurisdiction, so a new product should not assume that a legacy composition is interchangeable with another supplier’s formulation.

Typical excipient functions include:

Functional need	Suitable excipient categories	Formulation purpose
Dilution	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet weight and improves manufacturability
Binding	Povidone, copovidone, pregelatinized starch	Improves granule and tablet strength
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduces punch and die friction
Wetting	Sodium lauryl sulfate, poloxamers	Improves contact between drug particles and dissolution medium
Flow control	Colloidal silicon dioxide, talc	Improves powder flow and reduces sticking
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and improves identification
Stability control	Low-moisture excipients, opaque packaging, desiccants	Limits moisture-related degradation and physical changes

A practical immediate-release formulation would generally use a hydrophilic diluent, a high-efficiency disintegrant, a controlled lubricant level, and a wetting agent if dissolution testing shows inadequate release. The formulation should avoid excessive hydrophobic lubricant or overcompaction because either can slow dissolution.

How does tolbutamide solubility affect excipient selection?

Tolbutamide is a weak acid with limited aqueous solubility. Its dissolution can vary with pH, particle size, wetting, compression force, and the hydrodynamic conditions used during testing. PubChem identifies tolbutamide as a low-molecular-weight sulfonylurea with limited water solubility, a characteristic that affects oral solid-dose design (National Center for Biotechnology Information [NCBI], n.d.).

The highest-value excipient levers are:

1. Particle-size control for the active pharmaceutical ingredient.
2. Wetting and surfactant selection.
3. Rapid tablet disintegration.
4. Avoidance of excessive hydrophobic lubrication.
5. Control of granule porosity and compression force.
6. pH-sensitive dissolution testing.

A surfactant can improve wetting, but the level must be controlled. Excess surfactant may affect tablet strength, gastrointestinal tolerability, taste if the product is dispersed, and analytical method robustness. Sodium lauryl sulfate is a conventional option, but poloxamers or other nonionic surfactants may provide a different safety and compatibility profile.

A hydrophilic polymer such as povidone or copovidone can improve wetting and reduce segregation, but high binder levels may create dense granules that delay disintegration. The formulation target should be rapid, reproducible release rather than maximum mechanical strength.

What is the best immediate-release tolbutamide formulation strategy?

The most commercially efficient strategy is usually a conventional immediate-release tablet based on wet granulation or optimized dry granulation.

Wet granulation

Wet granulation is appropriate when the active pharmaceutical ingredient has poor flow, poor compactibility, or a broad particle-size distribution. It can improve content uniformity and reduce segregation in a high-dose 500 mg tablet.

Key controls include:

• Granulation endpoint.
• Residual moisture.
• Granule-size distribution.
• Compression force.
• Lubrication time.
• Dissolution after accelerated stability.

The main risk is overgranulation. Dense granules may reduce water penetration and delay drug release.

Direct compression

Direct compression can reduce process complexity and cost if the active and excipient blend has acceptable flow and compressibility. It may be attractive for a low-cost generic product, but tolbutamide’s relatively high tablet loading can make blend uniformity and tablet strength more difficult to control.

A direct-compression design should use excipients with strong compactibility, such as spray-dried lactose or silicified microcrystalline cellulose, while maintaining adequate disintegration.

Dry granulation

Roller compaction can reduce water exposure and may improve process efficiency. It is relevant where moisture sensitivity, solvent avoidance, or continuous manufacturing is a priority. Excessive compaction pressure can produce hard ribbons and slow tablet dissolution.

What formulation patents could protect a tolbutamide product?

New composition-of-matter protection for tolbutamide is not commercially realistic. The active ingredient has been known for many decades, and foundational patent protection has expired.

Potentially protectable subject matter would instead involve:

• A specific excipient ratio.
• A defined particle-size distribution.
• A manufacturing process that produces a distinctive dissolution profile.
• A taste-masked or dispersible dosage form.
• A modified-release system.
• A multiparticulate formulation.
• A stability-enhancing package or container-closure system.
• A combination product with a new clinical or technical rationale.
• A process that reduces impurities or improves batch consistency.

These claims would face substantial validity and obviousness pressure. A formulation patent is strongest when it links a narrow technical feature to a measured, reproducible performance benefit. Generic claims covering ordinary combinations of lactose, starch, povidone, and magnesium stearate would have limited defensive value.

What is the Orange Book status of tolbutamide?

Tolbutamide does not present a meaningful current Orange Book exclusivity opportunity. The Orange Book records approved prescription drug products, patents, and exclusivity information for eligible products, but a legacy active ingredient with expired protection does not create a modern branded barrier by itself (FDA, n.d.-b).

For a new applicant, the regulatory route would depend on the reference product and the availability of an FDA-recognized reference listed drug. A sponsor should distinguish among:

• An ANDA relying on a listed reference product.
• A 505(b)(2) application relying partly on published literature or FDA findings for a previously approved product.
• A full NDA if no suitable reference pathway is available.

The practical regulatory issue is not patent exclusivity. It is whether the applicant can establish an acceptable regulatory pathway, demonstrate pharmaceutical equivalence where required, and support product quality, labeling, manufacturing controls, and bioequivalence requirements.

When does tolbutamide lose exclusivity?

Tolbutamide’s original small-molecule exclusivity expired decades ago. No active ingredient exclusivity or patent term should be assumed to protect a modern tolbutamide tablet.

Protection type	Commercial assessment
Composition-of-matter patent	Expired
Original formulation protection	Expired or commercially irrelevant
New-drug exclusivity	Expired
Orphan exclusivity	Not applicable to the established product
Biosimilar exclusivity	Not applicable; tolbutamide is a small molecule
Modern branded moat	None apparent from the active ingredient alone
Potential new protection	Narrow formulation, process, device, or combination claims

A sponsor cannot rely on historical brand recognition to create exclusivity. Any commercial defense must come from supply reliability, regulatory execution, manufacturing cost, channel access, or differentiated dosage-form performance.

Are there Paragraph IV challenges for tolbutamide?

Paragraph IV litigation is unlikely to be commercially material for a conventional tolbutamide product because the foundational patent estate is long expired. Paragraph IV certification is relevant only where an applicable listed patent remains in the Orange Book for the reference product.

A new applicant should assess:

• Whether a reference listed drug remains available.
• Whether any patents are listed for the specific dosage form.
• Whether those patents cover the proposed product.
• Whether the filing strategy requires a Paragraph IV certification.
• Whether a Paragraph III certification or section viii statement is more appropriate for any listed method-of-use patent.

For an old active ingredient, regulatory timing and product availability are usually more important than patent litigation. A sponsor could still face litigation over a newly patented formulation or manufacturing process, but that would be a product-specific issue rather than a tolbutamide molecule issue.

What manufacturing and intellectual property barriers exist?

Manufacturing barriers are modest for a conventional tablet but can become material when the sponsor targets superior dissolution, lower impurity levels, or a specialized dosage form.

Manufacturing barriers

The principal technical risks are:

• API particle-size variability.
• Blend segregation in high-dose tablets.
• Slow dissolution caused by over-lubrication.
• Tablet capping or sticking.
• Moisture-driven changes in granule properties.
• Inconsistent assay across the tablet blend.
• Dissolution sensitivity to compression force.
• Limited API supplier redundancy.

A second-source API strategy is important because the product’s low price makes supply interruptions disproportionately damaging. The sponsor should qualify at least two suppliers where feasible and establish particle-size, polymorph, impurity, and residual-solvent specifications that are linked to dissolution performance.

Intellectual property barriers

A new formulation may obtain limited protection through:

• Narrow composition claims.
• Process claims tied to a validated dissolution profile.
• Stable solid-state forms, if technically distinct and patentable.
• Device or packaging claims for a differentiated dosage form.
• Combination-product claims with credible clinical utility.

The probability of broad, durable exclusivity is low. Freedom-to-operate analysis should focus on specific later-filed formulation and process patents, not expired tolbutamide compound patents.

What commercial opportunities exist for tolbutamide?

Tolbutamide has a limited but identifiable opportunity set.

Low-cost generic supply

A manufacturer can compete on:

• Reliable API supply.
• Low tablet cost.
• Consistent dissolution.
• Simple packaging.
• Institutional or government tenders.
• Markets where older sulfonylureas remain listed in treatment guidelines.

The product is most suitable for a lean manufacturing model. Extensive branding or premium packaging is unlikely to produce a strong return.

Regional and tender markets

Tolbutamide may retain demand in markets where older oral antidiabetic drugs remain available because of cost constraints. The opportunity depends on local registration status, prescribing practice, reimbursement, and procurement rules.

A regional strategy should prioritize countries with:

• Existing tolbutamide monographs.
• Established API supply.
• Government or institutional procurement.
• Low willingness to pay for newer therapies.
• A clear pathway for legacy generic registration.

Specialty dosage forms

Possible differentiation includes:

• Lower-dose tablets for titration.
• Scored tablets.
• Dispersible tablets.
• Oral powder or granules for patients with swallowing difficulties.
• Unit-dose packaging.
• Calendar packaging to support adherence.

These products may improve usability but would add regulatory and stability work. A dispersible or powder formulation would require careful taste, dose-uniformity, reconstitution, and microbial-control assessment.

Combination products

A tolbutamide combination with another antidiabetic agent could create a commercial rationale, but it would also increase regulatory complexity and clinical risk. The combination would need a current treatment rationale, a clear target population, and evidence that the product provides value compared with established combinations such as metformin-based regimens.

Contract manufacturing

Tolbutamide can fit a contract manufacturing portfolio for facilities that already produce immediate-release oral solids. The opportunity is strongest where the manufacturer can offer:

• Small and medium batch sizes.
• Flexible packaging.
• Multi-country regulatory support.
• Analytical method transfer.
• Stability programs.
• Dual-source API qualification.

How does tolbutamide compare with newer diabetes medicines?

Attribute	Tolbutamide	Glimepiride	Metformin	SGLT2 inhibitors	GLP-1 receptor agonists
Molecular age	Older	Older	Older	Newer	Newer
Hypoglycemia risk	Material	Material	Lower when used alone	Low when used alone	Low when used alone
Formulation complexity	Low	Low	Low to moderate	Low to moderate	High, often injectable or specialized
Patent opportunity	Minimal	Limited or expired at molecule level	Expired	Product-specific	Product-specific
Price position	Low	Low	Low	Higher	Higher
Commercial differentiation	Supply and cost	Supply and cost	Broad clinical use	Outcomes and convenience	Efficacy, weight, outcomes
Biosimilar exposure	None	None	None	None	None

Tolbutamide’s main disadvantage is clinical obsolescence relative to medicines with better durability, lower hypoglycemia risk, cardiovascular benefits, renal benefits, or weight-related advantages. Its main advantage is manufacturing simplicity and low cost.

What is the revenue exposure and launch risk?

Revenue potential is likely modest unless the product is sold into a protected procurement channel or a market with persistent demand for older oral antidiabetics. The launch case should be modeled around volume and gross margin, not premium pricing.

Key commercial risks include:

• Declining clinical use.
• Limited physician familiarity.
• Reimbursement exclusion.
• Low annual treatment volume.
• API supply concentration.
• Product discontinuation by competitors.
• Regulatory requirements for an old active ingredient.
• Safety-driven substitution by newer therapies.

A generic tolbutamide project is more defensible as a portfolio filler, tender product, or contract-manufacturing opportunity than as a standalone branded investment.

What is the recommended excipient and commercialization plan?

A practical development plan is:

1. Use a conventional immediate-release tablet as the lead product.
2. Screen direct compression and wet granulation in parallel.
3. Control API particle size and characterize dissolution across pH conditions.
4. Compare crospovidone, croscarmellose sodium, and sodium starch glycolate.
5. Evaluate a low-level wetting agent without compromising stability.
6. Minimize hydrophobic lubrication and verify dissolution after scale-up.
7. Use low-moisture packaging with an appropriate container-closure system.
8. Qualify multiple API sources.
9. Pursue the simplest viable FDA or national regulatory pathway.
10. Target tender, institutional, and regional channels before investing in consumer branding.

A differentiated product should claim a measurable performance benefit, such as consistent rapid release across API lots or improved stability under climatic stress. A conventional tablet without a cost or supply advantage will have limited commercial leverage.

Key Takeaways

• Tolbutamide is a legacy first-generation sulfonylurea with expired foundational exclusivity.
• The main formulation problem is low aqueous solubility and dissolution variability.
• A conventional immediate-release tablet remains the most commercially rational dosage form.
• Wetting agents, rapid disintegrants, particle-size control, and restrained lubrication are the key excipient levers.
• Broad formulation patent protection is unlikely; narrow process or composition claims may be available.
• Current commercial value is concentrated in low-cost supply, tenders, regional markets, and contract manufacturing.
• Tolbutamide has no biosimilar risk because it is a small molecule.
• Paragraph IV litigation is unlikely to be important unless a new product relies on a later-listed formulation patent.
• Newer antidiabetic therapies materially limit premium pricing and long-term demand.
• The strongest business case is a low-complexity, supply-reliable generic rather than a heavily differentiated branded product.

FAQs About Tolbutamide Excipient Strategy

Can lactose be used in tolbutamide tablets?

Yes. Lactose can function as a diluent and may support direct compression or granulation. Compatibility, moisture behavior, tablet hardness, and dissolution must be evaluated in the final formulation.

Which disintegrant is most suitable for tolbutamide?

Crospovidone, croscarmellose sodium, and sodium starch glycolate are reasonable candidates. The preferred choice depends on dissolution rate, compression conditions, tablet porosity, and stability data.

Does tolbutamide require a surfactant?

Not necessarily. A surfactant may improve wetting and dissolution, but it should be used only if development data show a meaningful benefit without creating stability, tolerability, or manufacturing problems.

Is a tolbutamide extended-release product commercially attractive?

Usually not as a first-line opportunity. An extended-release product would require additional formulation development, pharmacokinetic justification, and regulatory support in a market where newer therapies already offer broader clinical advantages.

Can a tolbutamide formulation receive new patent protection?

Potentially, but protection would likely be narrow. A patent position would need to rely on a technically distinct composition, manufacturing process, dosage form, or stability result that is novel, non-obvious, and reproducible.

References

1. National Center for Biotechnology Information. (n.d.). Tolbutamide. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Tolbutamide

2. U.S. Food and Drug Administration. (n.d.-a). Tolbutamide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.